Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.
Vallerand D, Massonnet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, Roman-Roman S, Savina A, Decaudin D. Vallerand D, et al. Among authors: weigand s. PLoS One. 2016 Jul 7;11(7):e0157670. doi: 10.1371/journal.pone.0157670. eCollection 2016. PLoS One. 2016. PMID: 27388901 Free PMC article.
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H, Le Tourneau C, Delord JP, van Herpen C, Mahalingam D, Coveler AL, Meresse V, Weigand S, Runza V, Cannarile M. Birzele F, et al. Among authors: weigand s. Clin Cancer Res. 2015 Jun 15;21(12):2753-62. doi: 10.1158/1078-0432.CCR-14-2141. Epub 2015 Mar 11. Clin Cancer Res. 2015. PMID: 25762343
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C. Menke-van der Houven van Oordt CW, et al. Among authors: weigand s. Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098. Oncotarget. 2016. PMID: 27507056 Free PMC article. Clinical Trial.
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muenter K, Radtke M, Schirok H, Schlemmer KH, Stahl E, Straub A, Wunder F, Stasch JP. Mittendorf J, et al. Among authors: weigand s. ChemMedChem. 2009 May;4(5):853-65. doi: 10.1002/cmdc.200900014. ChemMedChem. 2009. PMID: 19263460 Free article.
296 results